Amedisys (AMED) Moves to Buy: Rationale Behind the Upgrade
AMEDAmedisys(AMED) ZACKS·2024-10-01 01:00

Amedisys (AMED) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual investors ...